[Clinical analysis of 60 cases with malignant gastrointestinal stromal tumors].
OBJECTIVE
To investigate the clinicopathological characteristics, and treatment of malignant gastrointestinal stromal tumors (MGIST).


METHODS
Immunohistochemistry was used to detect CD117, CD34, S100, vimentin and SMA expressions. The postoperative curative effect was compared between the patients with or without imatinib treatment.


RESULTS
Radical resection was performed in 60 cases. Twenty-two tumors with a mean diameter of 5.3 cm were potentially malignant, and 38 tumor with a mean diameter of 9.2 cm were malignant. Microscopical examination revealed haemorrhagia or necrosis, abundant tumor cells, heteromorphism and caryocinesia of the tumors. 54 Cases were CD117 positive, 53 cases CD34 positive, 48 cases vimentin positive, 27 cases S100 positiveì16 cases SMA positive. The two-year recurrence rate was 80.5% in the patients without postoperative imatinib treatment, significantly higher than 21.1% in the patients with postoperative imatinib treatment(P< 0.05).


CONCLUSIONS
CD117 and CD34 markers are most valuable diagnostic indexes of MGIST, but its final diagnosis depends on pathology. Postoperative imatinib treatment is most effective to control recurrence and metastasis.
Lin
Fan
F
Department of General Surgery, The First People's Hospital of Guangzhou, Guangzhou 510180, China.
Cao
Jie
J
Xia
Jing-tang
JT
Huang
Chi-ming
CM
DU
Hong
H
Chen
Guo-qin
GQ
Wen
Min-jie
MJ
Dai
Li-hua
LH
Lai
Yue-yuan
YY
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit